Emerging Protein Biotherapeutics

Emerging Protein Biotherapeutics

Published:
Content:
Editor(s):
Free Standard Shipping

Purchasing Options

Hardback
$194.95
ISBN 9781420063202
Cat# 63200
Add to cart
eBook (VitalSource)
$194.95 $136.47
ISBN 9781420063219
Cat# E63200
Add to cart
SAVE 30%
eBook Rentals
Other eBook Options:
 
 

Features

    • Provides a comprehensive overview of protein biologics and their development for clinical applications
    • Covers the major areas currently targeted in solid tumors, hematological malignancies and autoimmune diseases
    • Includes contributions from leading international authorities
    • Includes a vivid color insert with detailed illustrations to bolster understanding

    Summary

    A Readily Applicable Framework for Novel Drug Design

    It is only 20 years since the reach of genetic knowledge has allowed for the development of protein biotherapeutics, but in that time the pace has been fast. While the literature abounds, the field has lacked a comprehensive accounting of this progress. Emerging Protein Biotherapeutics consolidates current knowledge of key protein targets important in autoimmunity and cancers, exploring basic aspects and diverse clinical application.

    Presents Strategies to Exploit Therapeutic Uses

    In this volume, leading researchers cover many aspects of biology related to protein targets, ranging from the in vivo role in the disease process, to various strategies exploiting development of these targets for therapeutic use. Each chapter includes background, a discussion of clinical implications, an account of preclinical and clinical testing of various candidates, and a listing of key references.

    This volume makes the study of protein biotherapeutics accessible at all levels of expertise. It offers an efficient and rational way to grasp the theoretical and experimental knowledge currently available while also providing a deeper understanding of disease processes. Most importantly, it presents a framework that can be readily employed by those looking to develop their own strategies in pursuit of new clinical applications.

    Table of Contents

    INTRODUCTION

    Overview of Antibody-Based Therapeutics: Present and Future Promise, I.S. Grewal

    BIOLOGICS FOR AUTOIMMUNITY AND INFLAMMATION

    Biologic Therapies for Multiple Sclerosis, P. Fontoura and H. Garren

    Biologic Therapies in Rheumatoid Arthritis, M.J. Houseman and J.D. Isaacs

    Biologic Therapies in Systemic Lupus Erythematosus, R. Eisenberg

    Biologic Therapies for Inflammatory Bowel Disease, M.H. Holtmann and M.F. Neurath

    Biologic Therapies for Psoriasis, R. Saraceno and S. Chimenti

    TNFa Inhibitors: Emerging Biologic Therapies for the Treatment of Asthma, S. Natarajan, L.J. Vaickus, J. Kim, and D.G. Remick

    Protein-Based Therapies in Experimental and Clinical Transplantation, G. Benichou, S. de Haseth, A.B. Cosimi, and A. Alessandrini

    Biologic Therapies for Type 1 Diabetes, T.L. Van Belle and M.G. von Herrath

    BIOLOGICS FOR HEMATOLOGICAL MALIGNANCIES

    Biologic Therapies for Acute Myeloid Leukemia/Myelodysplastic Syndrome, J. Pinilla-Ibarz and C. Bello

    Biologic Therapies for Non-Hodgkin Lymphoma and Hodgkin Disease, S.M. Ansell

    Biologic Therapies for Chronic Lymphocytic Leukemia, M.A. Kharfan-Dabaja and E.S. Santos

    Biologic Therapies for Multiple Myeloma and Plasma Cell Disorders, S. Ozaki

    DEVELOPMENT OF BIOTHERAPIES FOR SOLID TUMORS

    Antibody-Based Therapies for Carcinomas, D. Schrama and J.C. Becker

    Role of Vascular Targeting Agents in the Treatment of Solid Tumors: Current and Future Developments, H.-P. Gerber, I.S. Grewal, and E. Oflazoglu

    Recent Advancements in the Use of Antibody–Drug Conjugates for Cancer Therapy, P.D. Senter and D.R. Benjamin

    INDEX

    Editor Bio(s)

    Iqbal S. Grewal, Ph.D., is a well-established scientist and biotechnologist with many years of research in immunology and oncology. He has extensive experience in the discovery and development of innovative protein-based biotherapeutics in many disease areas. Some of Dr. Grewal’s findings have already helped to translate research into key drug candidates for the treatment of autoimmune diseases and cancers. Currently, he is serving as Vice President of Preclinical Therapeutics at Seattle Genetics and leading preclinical research for the development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology.

     
    Textbooks
    Other CRC Press Sites
    Featured Authors
    STAY CONNECTED
    Facebook Page for CRC Press Twitter Page for CRC Press You Tube Channel for CRC Press LinkedIn Page for CRC Press Google Plus Page for CRC Press Pinterest Page for CRC Press
    Sign Up for Email Alerts
    © 2014 Taylor & Francis Group, LLC. All Rights Reserved. Privacy Policy | Cookie Use | Shipping Policy | Contact Us